In the quest for a simple and effective biomarker for PD-1 antibody efficacy many candidates have emerged. The simplest one is the ratio between neutrophils and lymphocytes (NLR) in peripheral blood. Since 2012 the emergence of checkpoint inhibitor therapy has introduced a new paradigm in cancer therapy, adding a powerful tool in the oncology treatment armamentarium. The progress achieved in clinical trials have revealed efficacy in different tumor types and with different immunotherapy combinations. However optimal duration of therapy, optimal dose, optimal schedule, are for the most part unknown. In this review we will discuss the utility of information obtained from the peripheral blood CBC as a contributor to solving this question.
Key words: pd1, checkpoint inhibitors, neutrophil to lymphocyte ratio
|
